Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer

[1]  N. Reinmuth,et al.  PL02.11 Overall Survival with Durvalumab Plus Etoposide-Platinum in First-Line Extensive-Stage SCLC: Results from the CASPIAN Study , 2019, Journal of Thoracic Oncology.

[2]  M. Lawrence,et al.  Combination Olaparib and Temozolomide in Relapsed Small Cell Lung Cancer. , 2019, Cancer discovery.

[3]  A. Letai,et al.  MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancer , 2019, Nature Communications.

[4]  A. Berns,et al.  Tumor Heterogeneity Underlies Differential Cisplatin Sensitivity in Mouse Models of Small-Cell Lung Cancer , 2019, Cell reports.

[5]  Nicholas T. Ingolia,et al.  MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion , 2019, Clinical Cancer Research.

[6]  Paul J. Hoffman,et al.  Comprehensive Integration of Single-Cell Data , 2018, Cell.

[7]  C. Rudin,et al.  Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data , 2019, Nature Reviews Cancer.

[8]  E. Lobenhofer,et al.  P3.12-03 Targeting DLL3 with AMG 757, a BiTE® Antibody Construct, and AMG 119, a CAR-T, for the Treatment of SCLC , 2018, Journal of Thoracic Oncology.

[9]  P. Kim,et al.  c-MYC Drives Breast Cancer Metastasis to the Brain, but Promotes Synthetic Lethality with TRAIL , 2018, Molecular Cancer Research.

[10]  A. Mansfield,et al.  First‐Line Atezolizumab plus Chemotherapy in Extensive‐Stage Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[11]  Alex H. Wagner,et al.  Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer , 2018, Nature Communications.

[12]  D. Spector,et al.  POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer , 2018, Genes & development.

[13]  C. Rudin,et al.  Efficacy and safety of rovalpituzumab tesirine in patients with DLL3-expressing, ≥ 3rd line small cell lung cancer: Results from the phase 2 TRINITY study , 2018, Pneumologie.

[14]  Paul Hoffman,et al.  Integrating single-cell transcriptomic data across different conditions, technologies, and species , 2018, Nature Biotechnology.

[15]  Mehmet Toner,et al.  Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts. , 2018, Cancer discovery.

[16]  J. Minna,et al.  Small cell lung cancer tumors and preclinical models display heterogeneity of neuroendocrine phenotypes. , 2018, Translational lung cancer research.

[17]  J. Sage,et al.  Tumor heterogeneity in small cell lung cancer defined and investigated in pre-clinical mouse models. , 2018, Translational lung cancer research.

[18]  D. Torigian,et al.  Circulating tumor cells as a predictive biomarker in patients with small cell lung cancer undergoing chemotherapy. , 2017, Lung cancer.

[19]  Jing Wang,et al.  Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies , 2017, Oncotarget.

[20]  R. Zeillinger,et al.  Small cell lung cancer: model of circulating tumor cell tumorospheres in chemoresistance , 2017, Scientific Reports.

[21]  K. Garcia,et al.  Intratumoral heterogeneity generated by Notch signaling promotes small cell lung cancer , 2017, Nature.

[22]  Ying Feng,et al.  Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer , 2017, Oncotarget.

[23]  C. Rudin,et al.  Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis. , 2017, Cancer cell.

[24]  Kristofer C. Berrett,et al.  MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition. , 2017, Cancer cell.

[25]  R. Gronostajski,et al.  NFIB overexpression cooperates with Rb/p53 deletion to promote small cell lung cancer , 2016, Oncotarget.

[26]  J. Sage,et al.  Identification and Targeting of Long-Term Tumor-Propagating Cells in Small Cell Lung Cancer. , 2016, Cell reports.

[27]  Ji-Ying Song,et al.  Transcription Factor NFIB Is a Driver of Small Cell Lung Cancer Progression in Mice and Marks Metastatic Disease in Patients , 2016, Cell reports.

[28]  R. Zeillinger,et al.  Small cell lung cancer: Circulating tumor cells of extended stage patients express a mesenchymal-epithelial transition phenotype , 2016, Cell adhesion & migration.

[29]  Charles H. Yoon,et al.  Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq , 2016, Science.

[30]  Martin Vingron,et al.  Comprehensive genomic profiles of small cell lung cancer , 2015, Nature.

[31]  Michael Peyton,et al.  Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. , 2015, Cancer discovery.

[32]  T. Blum,et al.  Value of thyroid transcription factor (TTF)-1 for diagnosis and prognosis of patients with locally advanced or metastatic small cell lung cancer , 2015, Diagnostic Pathology.

[33]  Jia Zhou,et al.  Circulating Tumor Cells in Lung Cancer: Detection Methods and Clinical Applications , 2015, Lung.

[34]  Julie M Sheridan,et al.  edgeR: a versatile tool for the analysis of shRNA-seq and CRISPR-Cas9 genetic screens , 2014, F1000Research.

[35]  Yu Cao,et al.  Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing , 2014, Science.

[36]  Paul Theodor Pyl,et al.  HTSeq – A Python framework to work with high-throughput sequencing data , 2014, bioRxiv.

[37]  Mahmood Ayub,et al.  Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer , 2014, Nature Medicine.

[38]  Cole Trapnell,et al.  TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions , 2013, Genome Biology.

[39]  Yong Chen,et al.  SIBER: systematic identification of bimodally expressed genes using RNAseq data , 2013, Bioinform..

[40]  Michael Peyton,et al.  An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance , 2012, Clinical Cancer Research.

[41]  Michael Peyton,et al.  Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. , 2012, Cancer discovery.

[42]  Davis J. McCarthy,et al.  Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation , 2012, Nucleic acids research.

[43]  Robert B. Jenkins,et al.  MYC Gene Amplification is Often Acquired in Lethal Distant Breast Cancer Metastases of Unamplified Primary Tumors , 2011, Modern Pathology.

[44]  H. Hakonarson,et al.  ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data , 2010, Nucleic acids research.

[45]  Richard Durbin,et al.  Fast and accurate long-read alignment with Burrows–Wheeler transform , 2010, Bioinform..

[46]  Andrew R. Jamieson,et al.  Exploring nonlinear feature space dimension reduction and data representation in breast Cadx with Laplacian eigenmaps and t-SNE. , 2009, Medical physics.

[47]  Davis J. McCarthy,et al.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..

[48]  N. Tsubota,et al.  Circulating Tumor Cell as a Diagnostic Marker in Primary Lung Cancer , 2009, Clinical Cancer Research.

[49]  Ken Chen,et al.  VarScan: variant detection in massively parallel sequencing of individual and pooled samples , 2009, Bioinform..

[50]  Kevin R. Coombes,et al.  The Bimodality Index: A Criterion for Discovering and Ranking Bimodal Signatures from Cancer Gene Expression Profiling Data , 2009, Cancer informatics.

[51]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[52]  J. Minna,et al.  CNS metastases in small cell bronchogenic carcinoma. Increasing frequency and changing pattern with lengthening survival , 1979, Cancer.

[53]  C. Rudin,et al.  Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. , 2017, The Lancet. Oncology.

[54]  Claude-Alain H. Roten,et al.  Fast and accurate short read alignment with Burrows–Wheeler transform , 2009, Bioinform..